Clinical and hematologic features of patients with ITP included in the study
| Demographics and hematologic parameters at diagnosis . | All patients (N = 167) . | NGS pos (n = 31) . | NGS neg (n = 136) . |
|---|---|---|---|
| Median age (IQR), y | 57 (36-69) | 68 (60-77)∗ | 55 (32-67) |
| Males, n (%) | 92 (55%) | 22 (71%)∗ | 70 (51%) |
| Females, n (%) | 75 (45%) | 9 (29%) | 66 (49%) |
| Associated conditions, n (%) | 65 (39%) | 15 (48%) | 50 (37%) |
| Median follow-up (IQR), y | 5.5 (2-14) | 5.3 (3-16) | 5.5 (2-14) |
| Platelets, median (range), ×109/L | 34 (1-99) | 34 (1-99) | 34 (1-99) |
| Hb, median (range), g/dL | 13.9 (3.8-17.2) | 13.9 (6.3-16.9) | 13.9 (3.8-17.2) |
| Neutrophils, median (range), ×109/L | 3.7 (0.1-16.2) | 3.5 (1.3-8.8) | 3.8 (0.1-16.2) |
| Severe thrombocytopenia (PLT <30 × 103/μL), n (%) | 66 (40%) | 12 (39%) | 54 (40%) |
| Demographics and hematologic parameters at NGS | All patients (N = 167) | ||
| Median age (IQR), y | 63 (52-75) | 77 (67-80)∗ | 59 (50-72) |
| Years from diagnosis to NGS, median (IQR) | 3.6 (0.6-12.8) | 4.9 (1.3-14.5) | 3.6 (0.5-11.6) |
| Platelets, median (range), ×109/L | 50 (1-164) | 37 (3-139) | 53 (1-164) |
| Hb, median (range), g/dL | 13.3 (6.2-16.6) | 12.1 (7.6-16.3) | 13.5 (6.2-16.6) |
| Neutrophils, median (range), ×109/L | 3.9 (0.1-65) | 3.6 (0.3-11.5) | 3.9 (0.1-65) |
| Reticulocytes, median (range), ×109/L | 80 (1 – 292) | 64 (0.2-292) | 83 (2-286) |
| BM evaluation | n = 148 | n = 27 | n = 121 |
| BM cellularity percent, median (IQR) | 45 (30-55) | 40 (30-55) | 45 (30-54) |
| Hypocellularity, n (%) | 31 (21%) | 2 (7%) | 29 (24%) |
| Hypercellularity, n (%) | 46 (31%) | 13 (48%) | 33 (27%) |
| Dysplasia, n (%) | 72 (49%) | 13 (48%) | 59 (49%) |
| Reticulin fibrosis MF-1, n (%) | 42 (28%) | 8 (30%) | 34 (28%) |
| Cytogenetic aberrations, n (%) | 9 (6%) | 1 (4%) | 8 (7%) |
| Demographics and hematologic parameters at diagnosis . | All patients (N = 167) . | NGS pos (n = 31) . | NGS neg (n = 136) . |
|---|---|---|---|
| Median age (IQR), y | 57 (36-69) | 68 (60-77)∗ | 55 (32-67) |
| Males, n (%) | 92 (55%) | 22 (71%)∗ | 70 (51%) |
| Females, n (%) | 75 (45%) | 9 (29%) | 66 (49%) |
| Associated conditions, n (%) | 65 (39%) | 15 (48%) | 50 (37%) |
| Median follow-up (IQR), y | 5.5 (2-14) | 5.3 (3-16) | 5.5 (2-14) |
| Platelets, median (range), ×109/L | 34 (1-99) | 34 (1-99) | 34 (1-99) |
| Hb, median (range), g/dL | 13.9 (3.8-17.2) | 13.9 (6.3-16.9) | 13.9 (3.8-17.2) |
| Neutrophils, median (range), ×109/L | 3.7 (0.1-16.2) | 3.5 (1.3-8.8) | 3.8 (0.1-16.2) |
| Severe thrombocytopenia (PLT <30 × 103/μL), n (%) | 66 (40%) | 12 (39%) | 54 (40%) |
| Demographics and hematologic parameters at NGS | All patients (N = 167) | ||
| Median age (IQR), y | 63 (52-75) | 77 (67-80)∗ | 59 (50-72) |
| Years from diagnosis to NGS, median (IQR) | 3.6 (0.6-12.8) | 4.9 (1.3-14.5) | 3.6 (0.5-11.6) |
| Platelets, median (range), ×109/L | 50 (1-164) | 37 (3-139) | 53 (1-164) |
| Hb, median (range), g/dL | 13.3 (6.2-16.6) | 12.1 (7.6-16.3) | 13.5 (6.2-16.6) |
| Neutrophils, median (range), ×109/L | 3.9 (0.1-65) | 3.6 (0.3-11.5) | 3.9 (0.1-65) |
| Reticulocytes, median (range), ×109/L | 80 (1 – 292) | 64 (0.2-292) | 83 (2-286) |
| BM evaluation | n = 148 | n = 27 | n = 121 |
| BM cellularity percent, median (IQR) | 45 (30-55) | 40 (30-55) | 45 (30-54) |
| Hypocellularity, n (%) | 31 (21%) | 2 (7%) | 29 (24%) |
| Hypercellularity, n (%) | 46 (31%) | 13 (48%) | 33 (27%) |
| Dysplasia, n (%) | 72 (49%) | 13 (48%) | 59 (49%) |
| Reticulin fibrosis MF-1, n (%) | 42 (28%) | 8 (30%) | 34 (28%) |
| Cytogenetic aberrations, n (%) | 9 (6%) | 1 (4%) | 8 (7%) |
BM, bone marrow; Hb, hemoglobin; IQR, interquartile range; MF-1, marrow fibrosis 1; neg, negative; PLT, platelet count; pos, positive.
P < .05.